Jinwon Jung
Senior Director ABL Bio
Seminars
Tuesday 9th June 2026
NEOK002 (ABL209): Redesigning an EGFRxMUC1 Bispecific TOP1i ADC With Promising Anti-Tumor Activity & Enhanced Therapeutic Window
2:45 pm
- Introducing the development strategy of NEOK002 and discuss what differentiates it from existing EGFR/MUC1 targeting agents
- Exploring the pharmacological and toxicological characteristics of the differentiated features
- Discussing the clinical development potential secured through various preclinical studies
